Thompson Cancer Survival Center – Clinical Trials

Clinical Trials

Clinical trials are research studies designed to discover new ways to treat different cancers and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.

Thompson was the first to bring cancer clinical trials to East Tennessee over 25 years ago. Today, Thompson’s clinical trials department is under the leadership of Kristi Simcox, BS, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.

Thompson Cancer Survival Center offers clinical trials at the following Thompson Oncology Group locations:

Downtown Knoxville
Oak Ridge
West Knoxville
Thompson Proton Center

Our Team

Name	Title	Contact Info
Kristi Simcox, BS, CCRP	Systems Director of Clinical Research	[email protected] \| 865-331-4985
Jessica Severt, RN, BSN	Clinical Research Manager	[email protected] \| 865-331-4966
Ashley Lyons, RN	Study Coordinator	[email protected] \| 865-331-2586
Sarah France, RN	Study Coordinator	[email protected] \| 865-331-2587
Casey M., BS	Study Coordinator, Thompson Proton Center	[email protected] \| 865-331-8216
Christina Haller	Regulatory Specialist	[email protected] \| 865-331-1902
Catherine Duke-Taylor, BS	Study Coordinator, Thompson Proton Center	[email protected] \| 865-331-8215

Active Medical Oncology Clinical Trials

Breast

Protocol Number	NCT Number	Title	Principal Investigator
S2206	NCT06058377	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer	Rizwan Tariq, MD

Esophageal

Protocol Number	NCT Number	Title	Principal Investigator
NRG-GI006	NCT03801876	Phase iii randomized trial of proton beam therapy (pbt) versus intensity modulated photon radiotherapy (imrt) for the treatment of esophageal cancer	Grant Clark, MD

Melanoma

Protocol Number	NCT Number	Title	Principal Investigator
EA6141	NCT02339571	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma	David Graham, MD

Non-Small-Cell Lung Cancer

Protocol Number	NCT Number	Title	Principal Investigator
V940-002	NCT06077760	A PA Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)	Rizwan Tariq, MD

Active Proton Therapy Clinical Trials